Of the surface molecules overexpressed by MM cells, the B-cell Maturation Antigen (BCMA) is the most promising antigen, and therapeutic antibodies against BCMA have been rapidly developed with different technologies [15,16]. Here, TNFRSF17 is linked to Miyoshi myopathy.